Background {#Sec1}
==========

Acetylsalicylic acid (commonly referred to as "aspirin") is an antithrombotic agent that inhibits platelets by irreversibly acetylating the serine residue of cyclooxygenase-1 (COX-1) in platelets with subsequently reduced levels of prothrombotic thromboxane A~2~ (TxA~2~) \[[@CR1]--[@CR3]\]. In patients with known cardiovascular disease (CVD), the potential for aspirin to reduce further cardiovascular (CV) events significantly outweighs the risks of major bleeding and thus aspirin has since become a mainstay in secondary prevention of CVD \[[@CR4]--[@CR8]\]. However, in primary prevention, its role is still under debate \[[@CR9]\]. This is due to an as yet unclear balance between the benefits and risks of aspirin treatment in patients without a diagnosed atherosclerotic disease.

Previously published meta-analyses have indicated that aspirin significantly reduced myocardial infarction (MI) and major adverse cardiovascular events (MACE) without an impact on stroke and CV- or all-cause death \[[@CR10]--[@CR14]\]. Furthermore, an increased risk of major bleeding events under aspirin strongly outweighed the benefits of aspirin treatment in primary prevention \[[@CR10], [@CR12]--[@CR14]\]. As a result, the current guidelines on CVD prevention from the European Society of Cardiology (ESC) do not recommend antiplatelet therapy in patients free of overt CVD \[[@CR8]\]. On the contrary, the recently published 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease states that aspirin might be considered in selected adults aged 40 to 70 who are at higher CV risk but at no increased bleeding risk \[[@CR15]\]. The U.S. Preventive Services Task Force recommends initiation of aspirin treatment depending on age and 10-year CVD risk \[[@CR16]\].

Recently, three major trials (ARRIVE, ASCEND, and ASPREE) evaluating the use of aspirin in primary prevention of CVD were published \[[@CR17]--[@CR19]\]. The ARRIVE trial enrolled patients with moderate to high cardiovascular risk, the ASCEND trial patients with diabetes mellitus (DM) only, and the ASPREE trial elderly patients. Only the ASCEND trial \[[@CR18]\] showed a significant reduction in the rate of major adverse CV events, but the effect was, once again, accompanied by a significant increase in major bleeding. Using the three recently published trials, we aimed to perform a meta-analysis with a particular focus on subgroups in order to potentially characterize patient populations with a more favorable benefit-risk ratio.

Methods {#Sec2}
=======

Protocol and registration, data extraction, and quality assessment {#Sec3}
------------------------------------------------------------------

Our review was registered with PROSPERO under the registration number CRD42019118474. Two reviewers applied the selection criteria (GG and JMSM) independently and in duplicate. This study was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, as described previously \[[@CR20]--[@CR24]\].

Data sources and searches {#Sec4}
-------------------------

We searched PubMed and Web of Science using predefined search terms (primary prevention AND aspirin AND clinical trial OR meta-analysis) until November 2018. Six additional trials \[[@CR25]--[@CR30]\] that were included in a previous meta-analysis \[[@CR5]\] were also identified and included in our analysis. The titles and abstracts of suspected relevant citations were screened for eligibility, and the full text was acquired for further evaluation if the citation was deemed pertinent. References of retrieved meta-analyses and reviews were also checked for additional trials.

Study selection and outcomes {#Sec5}
----------------------------

Included studies had to be randomized controlled trials (RCT) and include at least 1000 patients. Studies had to be controlled (placebo or control group), but could be open-label or blinded. The target patient population comprised patients without any history of CVD. Patients with a low ankle-brachial index (ABI) who had no symptoms and no diagnosis of peripheral arterial disease were considered as a primary prevention cohort. Exclusion criteria were non-RCTs, duplicate reports, ongoing studies, and studies that included patients with history of CVD.

The primary efficacy outcome was all-cause mortality. Secondary efficacy outcomes included cardiovascular mortality, the composite of major adverse cardiovascular events (MACE), MI, and ischemic stroke (IS). MACE was defined as a composite of nonfatal stroke, nonfatal MI, and CV mortality. In order to accurately assess the rate of MACE, we performed two analyses, one comparing the calculated rate of MACE as per our definition and one comparing the rate of the study defined primary outcome as a part of a sensitivity analysis. Stroke was defined as "ischemic stroke" but not all included studies reported on the incidence of IS alone. If not sufficiently specified, the number of reported strokes was used. We also reported on the incidence of hemorrhagic stroke. Bearing in mind the uncertain effect of aspirin on cancer outcomes, cancer risk was prespecified as an exploratory outcome. For further analysis of data, we performed four subgroup analyses involving diabetes, sex, concomitant statin treatment, and smoking.

Major bleeding was the primary safety endpoint. Definition of major bleeding varied between studies. If not defined as "major bleeding," we used the following definitions: "bleeding requiring transfusion," "bleeding rendering patients intensive care dependent," "bleeding causing death," or "intracranial bleeding." The extracranial major bleeding analysis comprised the total of all major bleedings and some GI bleeding events that were classified as relevant in respect to the analysis. Intracranial hemorrhages and GI bleedings were also assessed as single endpoints.

Data synthesis and analysis {#Sec6}
---------------------------

Variables are reported as numbers or percentages as appropriate. Risk ratios (RR) were calculated from individual studies and pooled according to the inverse variance model with 95% confidence intervals (95% CI) and reported as relative risk reduction or increase respectively (RRR/RRI) within a mean time frame of 6.4 years (which is the mean follow-up period of included studies). The statistical inconsistency test (*I*^2^) was used to assess heterogeneity vs. homogeneity between studies. If the *I*^2^ value was low (*I*^2^ \< 50%), a fixed-effect model was additionally calculated, as reported previously \[[@CR20], [@CR22], [@CR24]\]. The following sensitivity analyses were performed: (i) comparison of the results of the fixed vs. random-effect model, (ii) the influence of each study was assessed by testing whether deleting each in turn would have significantly changed the pooled results of the meta-analysis, (iii) sensitivity analysis of the date of publication before and after 2010, (iv) sensitivity analysis assessing the length of follow-up (\< 5 vs. \> 5 years), and (v) and analysis focusing on the study defined primary outcome parameter.

Absolute risk reduction or increase (ARR, ARI) and number needed to treat or harm (NNT, NNH) were calculated per 1 year of treatment. This was performed as follows: event incidence rates were divided by their respective mean follow-up periods and multiplied by 100 to obtain the incidence rate per 100 patient years. Out of these, the ARR or ARI were calculated by subtraction, and subsequently, the NNT or NNH were calculated according to the following formula: NNT or NNH = 1/(ARR or ARI). Events prevented/caused per 10,000 patients per year were calculated by dividing 10,000 by the NNT or NNH. This transformation of data allows for a better understanding of risks for doctors and patients.

The mortality-adjusted net clinical benefit was calculated as follows: \[IR~ischemi\ stroke_aspirin~ + w1IR~myocardial\ infarction_aspirin~ + w2IR~hemorrhagic\ stroke_aspirin~ + w3IR~major\ extracranial\ bleeding_aspirin~\] − \[IR~ischemic\ stroke_control~ + w1IR~myocardial\ infarction_control~ + w2IR~hemorrhagic\ stroke_control~ + w3IR~major\ extracranial\ bleeding_control~\], where w1, w2, and w3 are the death-related weights associated with each type of event. Weights were calculated as the impact of each event on mortality, as derived from recent analyses \[[@CR31], [@CR32]\], and related to IS (weight = 1). Weights were thus w1 = 0.89 for MI, w2 = 3.23 for hemorrhagic stroke, and w3 = 0.63 for major extracranial bleeding \[[@CR31], [@CR32]\]. In the mortality-adjusted net clinical benefit analysis, a lower estimate indicates a greater benefit of aspirin.

A two-tailed *p* value of \< 0.05 was considered significant. Review Manager (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used for statistical calculations.

Results {#Sec7}
=======

Description of studies {#Sec8}
----------------------

Our search retrieved 608 references. Five hundred ninety items were excluded based on title and abstracts that were not RCTs, investigated aspirin in secondary prevention of CVD, or were identified as non-pertinent studies (Additional file [1](#MOESM1){ref-type="media"}: Figure S1). Additionally, retrieved reviews and meta-analyses were thoroughly examined to identify further trials. One study was excluded as it contained a significant number of patients with definite or suspected CVD \[[@CR33]\]. Thirteen trials \[[@CR17]--[@CR19], [@CR25]--[@CR30], [@CR34]--[@CR37]\] were eligible for analysis and comprised a total of 164,225 patients, 82,900 allocated to aspirin and 81,325 allocated to the control group. One included study \[[@CR36]\] was a 10-year follow-up of a previously published trial \[[@CR38]\]. The mean age of patients included in our meta-analysis was 62 years. The mean follow-up period was 6.4 years (ranged from 3.6 to 10.3 years). Three trials exclusively included patients with known diabetes \[[@CR18], [@CR36], [@CR37]\]. Three trials included men only \[[@CR25], [@CR28], [@CR30]\], and one trial included women only \[[@CR29]\]. The dosage of aspirin ranged from 75 to 500 mg once daily. Two trials evaluated the effect of aspirin (325 mg and 100 mg) given on alternate days \[[@CR29], [@CR30]\]. Only two studies reported the use of proton-pump inhibitors (PPIs) \[[@CR18], [@CR19]\]. Included studies are characterized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Table 1Characteristics of included studiesStudyStudy designStudy populationInclusion criteriaExclusion criteriaMedian follow-upPrimary endpointAspirin treatment regimen*N*Placebo-controlledPeto et al. \[[@CR28]\] (British Doctors' Study)Open-label RCTMale British doctorsMale doctors residing in the UK and listed in the 1977 Medical Directory who previously replied to a questionnaire about their smoking habits-Ongoing aspirin use-History of peptic ulcer, strike or myocardial infarction6 yearsMyocardial infarction, stroke, transient ischemic attacks500 mg once daily5139NoSteering Committee of the Physicians' Health Study Research Group \[[@CR30]\] US Physicians' Health Study 1989 (PHS)Double-blind RCTHealthy male doctors-Male physician-40 to 84 years of age-History of myocardial infarction, stroke, transient ischemic attack, cancer (except nonmelanoma skin cancer)-Current liver or kidney disease-Peptic ulcer-Gout-Contraindications to aspirin consumption-Current use of aspirin, other platelet-active drugs, nonsteroidal anti-inflammatory drugs, or current use of vitamin A supplement5 yearsMyocardial infarction, stroke, cardiovascular mortality325 mg on alternate days22,071YesThe Medical Research Council's General Practice Research Framework \[[@CR25]\] Thrombosis Prevention Trial 1998 (TPT)Double-blind RCTMen at high risk of IHD-Males between age 46 and 69-Top 20% of risk score distribution-Top 25% in regions with particularly high ischemic heart disease (IHD) mortality rates-Peptic ulceration-History of possible or definite myocardial infarction or stroke-Medication not compatible with trial treatment6.8 yearsAll IHD (sum of coronary death and fatal and nonfatal myocardial infarction)75 mg once daily5085YesHansson et al. \[[@CR27]\] (Hypertension Optimal Treatment Trial, HOT)Double-blind RCTMen and women with hypertension-Age 50 to 80 years-Hypertension-Diastolic blood pressure between 100 and 115 mmHg-Suspicion of incorrect inclusion or data handling3.8 yearsMACE was defined as all (fatal and nonfatal) myocardial infarctions and strokes and all other cardiovascular deaths75 mg once daily18,790YesCollaborative Group of the Primary Prevention Project \[[@CR26]\] Primary Prevention Project (PPP) 2001Open-label RCTMen and women with one or more risk factors for coronary heart disease (CHD)-Age \> 65 years-Hypertension (SBP ≥ 160, DBP ≥ 95)-Hypercholesterolemia-Diabetes mellitus-Obesity-Family history of myocardial infarction before 55 years of age in at least one parent or sibling-Treatment with antiplatelet drugs, chronic-Chronic use of anti-inflammatory drugs or anticoagulants-Contraindications to aspirin-Disease with predictable poor short-term prognosis-Predictable psychological or logistical difficulties affecting compliance with the trial requirements3.6 yearsCumulative rate of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke100 mg once daily4495No (vitamin E)Ridker et al. \[[@CR29]\] (Women's Health Study, WHS)Double-blind RCTFemales aged 45 and over-Women aged ≥ 45-No history of coronary heart disease, cerebrovascular disease, cancer (except nonmelanoma skin cancer), other major chronic illnesses-History of side-effects to any of the study medications-Intake of aspirin or nonsteroidal anti-inflammatory drugs more than once a week-Use of anticoagulants or corticosteroids-Intake of supplements of vitamins A and E and beta-carotene more than once a week10.1 yearsNonfatal myocardial infarction, nonfatal stroke, or death from any cardiovascular causes100 mg on alternate days39,876YesBelch et al. \[[@CR37]\] (POPADAD trial)Double-blind RCTDiabetic patients aged 40 and over with a reduced ABI-Men and women aged ≥ 40-Diagnosis of type I or II diabetes mellitus-Asymptomatic peripheral artery disease (ABI ≤ 0.99)-Evidence of symptomatic cardiovascular disease-Use of aspirin or antioxidant therapy-Peptic ulceration, severe dyspepsia-Bleeding disorder-Intolerance to aspirin-Suspected serious physical illness with reduced life expectancy-Congenital heart disease-Psychiatric illness6.7 yearsTwo hierarchical composite primary endpoints: (1) death from coronary heart disease or stroke, nonfatal myocardial infarction or stroke, or above ankle amputation for critical limb ischemia and (2) death from coronary heart disease or stroke100 mg once daily1276YesOgawa et al. \[[@CR38]\] (Saito et al. \[[@CR36]\], 10-year follow-up) (JPAD trial)Open-label RCTPatients with diabetes-Age between 30 and 85 years-Type 2 diabetes mellitus-Ability to give informed consent-Ischemic ECG abnormalities-History of CHD-History of coronary angiography-History of cerebrovascular disease-History of arteriosclerotic disease requiring treatment-Atrial fibrillation-Pregnancy-Use of antiplatelet/antithrombotic therapy-History of severe gastric or duodenal ulcer-Severe renal or liver dysfunction-Allergy to aspirin4.4 years/10.3 yearsAny atherosclerotic event, which was a composite of sudden death, death from coronary, cerebrovascular or aortic causes, nonfatal acute myocardial infarction, unstable angina, newly developed exertional angina, nonfatal ischemic and hemorrhagic stroke, transient ischemic attack, nonfatal aortic or disease81--100 mg once daily2539NoFowkes et al. \[[@CR34]\] (Aspirin for Asymptomatic Atherosclerosis trial, AAA)Double-blind RCTMen and women with a low ABI-Men and women aged 50 to 75 years-No history of vascular disease-ABI ≤ 0.95-History of myocardial infarction, stroke, angina, or peripheral artery disease-Use of antiplatelet/antithrombotic therapy-Severe renal or liver dysfunction-Severe indigestion-Receiving chemotherapy-High/low hematocrit-Contraindication to aspirin8.2 yearsComposite of initial fatal or nonfatal coronary event or stroke or revascularization100 mg once daily3350YesIkeda et al. \[[@CR35]\] (Japanese Primary Prevention Trial, JPPP)Open-label RCTMen and women with one or more risk factors for CHD-Men and women aged 60 to 85 years-No atherosclerotic disease-Hypertension (SBP ≥ 140, DBP ≥ 90)-Dyslipidemia-Diabetes mellitus-History of coronary artery disease-History of cerebrovascular disease-Atherosclerotic disease requiring surgery-Atrial fibrillation-Peptic ulcer or conditions associated with bleeding-Aspirin-sensitive asthma and history of aspirin allergy-Receiving antiplatelet agents, anticoagulants, or nonsteroidal anti-inflammatory drugs5 yearsComposite of death from cardiovascular causes (myocardial infarction, stroke, and other cardiovascular causes), nonfatal stroke, and nonfatal myocardial infarction100 mg once daily14,464NoGaziano et al. \[[@CR17]\] (ARRIVE trial)Double-blind RCTMen and women with multiple risk factors for CHD-Males aged 55 years and older with between 2 and 4 risk factors-Females aged 60 years and older with between 3 and 4 risk factors-Risk factors were high cholesterol or LDL-Current smoking-Low HDL cholesterol-High blood pressure-Receiving medication for high blood pressure-Positive family history of cardiovascular heart disease-Diabetes mellitus-History of a vascular event, such as stroke, myocardial infarction, coronary artery angioplasty, or stenting-Coronary artery bypass graft-Relevant arrhythmias-Congestive heart failure-Vascular intervention-Ongoing antiplatelet therapy-High risk of gastrointestinal and other bleeding, including those with a history of gastric or duodenal ulcers or gastrointestinal bleeding-Requiring concomitant use of anticoagulants or frequent use of nonsteroidal anti-inflammatory drugs5 yearsComposite outcome of confirmed myocardial infarction, stroke, cardiovascular death, unstable angina, or transient ischemic attack100 mg once daily12,546YesThe ASCEND Study Collaborative Group \[[@CR18]\] (ASCEND trial) 2018Single-blind RCTDiabetic men and women aged ≥ 40-Men and women with at least 40 years of age-Diagnosis of diabetes mellitus-No known cardiovascular disease-Clear indication for aspirin-Contraindication to aspirin-Presence of other clinically significant conditions that might limit adherence to the trial regimen for at least 5 years7.4 yearsFirst serious vascular event, which was defined as a composite of nonfatal myocardial infarction, nonfatal stroke (excluding confirmed intracranial hemorrhage) or transient ischemic attack, or death from any vascular cause (excluding confirmed intracranial hemorrhage)100 mg once daily15,480YesMcNeil et al. \[[@CR19]\] (ASPREE trial)Double-blind RCTElderly men and women-Men and women aged ≥ 70 (≥ 65 in Hispanics and Latinos)-Free from overt coronary heart disease, overt cerebrovascular disease, atrial fibrillation, a clinical diagnosis of dementia, clinically significant physical disability, a high risk of bleeding, anemia, and a known contraindication to or inability to take aspirin-Current regular use of an anticoagulant or antiplatelet medication other than aspirin-Systolic blood pressure of 180 mmHg or more or a diastolic blood pressure of 105 mmHg or more-A medical indication for or contraindication to regular aspirin therapy-Presence of a condition that, in the opinion of the primary care physician, was likely to result in death within 5 years4.7 yearsPrespecified secondary endpoint was cardiovascular disease, being a composite of fatal coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal stroke, or hospitalization for heart failure100 mg once daily19,114Yes Table 2Overview of study demographicsStudyPatients includedMean age \[years\]Mean follow-up \[years\]% statin use% PPI use% diabetes% maleBritish Doctors' Study5139616UnknownUnknown2100US Physicians' Health Study22,071535UnknownUnknown2100Thrombosis Prevention Trial5085576.8UnknownUnknown2100Hypertension Optimal Treatment Trial18,790613.8UnknownUnknown853Primary Prevention Project4495643.6UnknownUnknown1743Women's Health Study39,8765410.1UnknownUnknown30POPADAD trial1276606.7UnknownUnknown10044JPAD trial25396510.3268.6\*\*10055AAA trial3350628.2UnknownUnknown328JPPP trial14,464715UnknownUnknown3442ARRIVE trial12,546645UnknownUnknown070ASCEND trial15,480637.475Approx. 2594.163ASPREE trial19,11474\*4.73424.71144all studies included164,225626.4 (IQR 4.85--7.8)\*Median age\*\*Labeled as antiulcer medication

Efficacy and safety outcomes {#Sec9}
----------------------------

All trials reported on all-cause mortality \[[@CR17]--[@CR19], [@CR25]--[@CR30], [@CR34]--[@CR37]\] and included 164,225 patients. The incidence of all-cause mortality was similar between the aspirin and control groups (4.52% vs. 4.54%, respectively; RR 0.98; 95% CI, 0.93--1.02; *p* = 0.26; *I*^2^ = 0%; Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S2A). Use of aspirin was not associated with a reduction in CV mortality (RR 0.99; 95% CI, 0.90--1.08; *p* = 0.75; *I*^2^ = 0%; Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}; Additional file [1](#MOESM1){ref-type="media"}: Figure S3A) compared with no aspirin. Aspirin was associated with a RRR of MACE by 9% (RR 0.91; 95% CI, 0.86--0.95; *p* \< 0.0001; *I*^2^ = 0%; ARR 0.052%; NNT 1908; Fig. [1](#Fig1){ref-type="fig"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S2B), of MI by 14% (RR 0.86; 95% CI, 0.77--0.95; *p* = 0.005; *I*^2^ = 50%; ARR 0.041%; NNT 2452; Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S3B), and of IS by 10% (RR 0.90; 95% CI, 0.82--0.99; *p* = 0.03; *I*^2^ = 17%; ARR 0.022%; NNT 4448; Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S3C) compared with no aspirin. Fig. 1Risk ratios (RR) of the major outcomes Table 3Risk estimates: absolute risk reduction (ARR) or increase (ARI) and number needed to treat (NNT) or to harm (NNH) for the primary and secondary endpoints over a treatment period of 1 year, which were statistically different between groupsEventEvents per 100 patient years in the aspirin groupEvents per 100 patient years in the control groupARR %ARI %NNTNNHEvents prevented per 10,000 treated patientsEvents caused per 10,000 treated patients*p* valueMyocardial infarction0.2600.3010.041245240.005Ischemic stroke0.2180.2400.022444820.03MACE0.6130.6650.05219085\< 0.0001Major bleeding0.2570.1800.07712958\< 0.0000Extracranial major bleeding0.2860.2180.06814627\< 0.0000GI bleeding0.3990.3200.07912638\< 0.0001

Twelve studies, including a total of 159,086 patients, reported on the rate of major bleeding complications \[[@CR17]--[@CR19], [@CR25]--[@CR27], [@CR29], [@CR30], [@CR34]--[@CR37]\]. Aspirin use was associated with a 46% RRI of major bleeding complications (RR 1.46; 95% CI, 1.30--1.64; *p* \< 0.00001; *I*^2^ = 31%; ARI 0.077%; NNH 1295; Fig. [1](#Fig1){ref-type="fig"}, Table [3](#Tab3){ref-type="table"}, Additional file [1](#MOESM1){ref-type="media"}: Figure S2C) compared with no aspirin. Extracranial major bleedings and GI bleedings were the major driver of the composite of bleeding events, with intracranial bleedings and hemorrhagic stroke having no statistical impact (Additional file [1](#MOESM1){ref-type="media"}: Figure S4). Aspirin did not decrease the cancer incidence (Additional file [1](#MOESM1){ref-type="media"}: Figure S5).

The net clinical benefit {#Sec10}
------------------------

All trials \[[@CR17]--[@CR19], [@CR25]--[@CR30], [@CR34]--[@CR37]\] provided data for the estimation of the *adjusted* net clinical benefit. Aspirin was not associated with a net clinical benefit after adjustment for event-associated mortality risk (mean 0.034%; 95% CI, − 0.184 to 0.252%; Fig. [2](#Fig2){ref-type="fig"}). Fig. 2Analysis of the mortality-adjusted net clinical benefit

The *crude* net clinical benefit comprising MACE and major bleeding events was calculated with data from 12 studies \[[@CR17]--[@CR19], [@CR25]--[@CR27], [@CR29], [@CR30], [@CR34]--[@CR37]\], showing that aspirin did not lead to a net clinical benefit (RR 1.01; 95% CI, 0.97--1.05; *p* = 0.54; *I*^2^ = 0%; Additional file [1](#MOESM1){ref-type="media"}: Figure S6).

Analysis of subgroups {#Sec11}
---------------------

### Statin treatment {#Sec12}

#### MACE: {#FPar1}

Two trials, comprising a total of 34,594 patients, reported on the MACE risk in patients with and without statin treatment \[[@CR18], [@CR19]\]. Aspirin-treated patients who were also treated with statins had a 12% RRR of MACE when compared with control plus statin (RR 0.88; 95% CI, 0.80--0.96; *p* = 0.007; *I*^2^ = 0%; Fig. [3](#Fig3){ref-type="fig"}). In contrast, aspirin without statin co-treatment did not reduce MACE risk when compared with control without statin (RR 0.94; 95% CI, 0.83--1.08; *p* = 0.39; *I*^2^ = 25%; Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Subgroup analysis: Forest plot depicting the relative risk (RR) of MACE in patients with and without statin treatment

### Smoking {#Sec13}

#### MACE: {#FPar2}

Five trials, comprising a total of 88,539 patients, reported on incidence of MACE in smokers and non-smokers \[[@CR17], [@CR19], [@CR29], [@CR35], [@CR36]\]. In non-smokers, aspirin use was associated with a 10% RRR of MACE (RR 0.90; 95% CI, 0.82--0.99; *p* = 0.04; *I*^2^ = 23%; Fig. [4](#Fig4){ref-type="fig"}) compared with no aspirin. In smokers, aspirin did not affect the risk of MACE (RR 1.11; 95% CI, 0.96--1.28; *p* = 0.16; *I*^2^ = 0%; Fig. [4](#Fig4){ref-type="fig"}). Fig. 4Subgroup analysis: Forest plot depicting the relative risk (RR) of MACE in smokers and non-smokers

### Sex {#Sec14}

#### MACE: {#FPar3}

Nine trials, including 59,337 patients, reported the incidence of MACE in men \[[@CR18], [@CR19], [@CR25], [@CR28], [@CR30], [@CR34]--[@CR37]\], seven trials in women (69,164 patients) \[[@CR18], [@CR19], [@CR29], [@CR34]--[@CR37]\]. There was a sex interaction for aspirin effect: the direction of the effect of aspirin on MACE tended to be similar in men and women, but the effect size differed, and did not reach statistical significance in females. Aspirin in men was associated with a RRR of MACE of 11% (RR 0.89; 95% CI, 0.83--0.95; *p* = 0.0008; *I*^2^ = 12%; Fig. [5](#Fig5){ref-type="fig"}) compared with controls. In women, aspirin did not significantly reduce the risk of MACE (RR 0.95; 95% CI, 0.88--1.02; *p* = 0.16; *I*^2^ = 0%; Fig. [5](#Fig5){ref-type="fig"}) compared with controls. Fig. 5Subgroup analysis: Forest plot depicting the relative risk (RR) of MACE in males and females

#### Myocardial infarction: {#FPar4}

Three trials, including 32,295 patients, reported on MI in men \[[@CR25], [@CR28], [@CR30]\], only one in women (39,876 patients) \[[@CR29]\]. In men and in women, aspirin did not significantly reduce the risk of MI (RR 0.76; 95% CI, 0.57--1.01; *p* = 0.06; *I*^2^ = 76%; RR 1.03; 95% CI, 0.84--1.25; *p* = 0.26; respectively). This is in contrast to the overall population and underlines that the sex sub-analysis for MI is underpowered.

#### Ischemic stroke: {#FPar5}

Three trials, including 32,295 patients, reported on IS in men \[[@CR25], [@CR28], [@CR30]\], but only one trial reported these data for women (39,876 patients) \[[@CR29]\]. Aspirin did not reduce the RR of IS in men (RR 1.02; 95% CI, 0.72--1.44; *p* = 0.93; *I*^2^ = 55%). In women, however, aspirin reduced IS by 23% (RR 0.77; 95% CI, 0.63--0.94; *p* = 0.010) compared to control as reported in one study.

### Diabetes {#Sec15}

#### MACE: {#FPar6}

Six studies, including 27,292 patients, reported on the rate of primary endpoint in patients with diabetes, showing a RRR of MACE by 9% (RR 0.91; 95% CI, 0.85--0.99; *p* = 0.02; *I*^2^ = 0%, Fig. [6](#Fig6){ref-type="fig"}), which is consistent with the analysis of the overall population. No data for a non-diabetic subgroup were available. Fig. 6Subgroup analysis: Forest plot depicting the relative risk (RR) of MACE in patients with diabetes

#### Myocardial infarction: {#FPar7}

Five studies, comprising 20,865 patients, provided data for MI in diabetic patients, showing no difference between aspirin vs. control (RR 0.94; 95% CI, 0.72--1.23; *p* = 0.65; *I*^2^ = 53%) \[[@CR18], [@CR29], [@CR30], [@CR36], [@CR37]\].

#### Ischemic stroke: {#FPar8}

Four studies, including 20,332 patients, reported on IS in diabetic patients, showing a RRR of IS by aspirin of 24% (RR 0.76; 95% CI, 0.59--0.98; *p* = 0.03; *I*^2^ = 43%) \[[@CR18], [@CR29], [@CR36], [@CR37]\].

#### Sensitivity analyses: {#FPar9}

Sensitivity analysis assessing the date of publication showed that the direction of the effect on MACE remained unchanged. However, the magnitude of the effect tended to be greater in studies published before 2010 compared to studies published after this date (RRR 11% vs. 7%, respectively).

Due to low heterogeneity (*I*^2^ = 0%), a fixed-effect model was calculated in addition to the random-effect model for each outcome (Additional file [1](#MOESM1){ref-type="media"}: Table S1), which confirmed the robustness of our findings.

By sequentially excluding one single study from the pooled analysis, the direction and the magnitude of the effect on MACE remained unchanged.

Sensitivity analysis assessing the length of follow-up/length of study drug use showed that the direction of effect on MACE remained unchanged. However, the magnitude of the effect tended to be greater in studies with a shorter-term use of aspirin (≤ 5 years, RRR 13%) vs. longer-term use (\> 5 years, RRR 8%).

We additionally analyzed the primary endpoint of each study according to the study definition (which in some studies slightly differed from the MACE definition used in our meta-analysis). In the aspirin group, 4.3% of patients (3601/82,900) reached the primary endpoint compared to 4.7% in the control group (3827/81,325). Treatment with aspirin, therefore, significantly reduced the RR of the primary endpoint by 9% (RR 0.91; 95% CI, 0.87--0.95; *p* \< 0.0001; *I*^2^ = 0%), confirming the result of the MACE analysis.

Discussion {#Sec16}
==========

Our meta-analysis in over 160,000 patients without a history of CVD showed that aspirin did not reduce all-cause or CV mortality but reduced the risk of MACE, MI, and IS at the cost of an increased risk of major bleeding events. Hence, aspirin treatment was associated with a lower NNH than the NNT for the safety and efficacy outcomes: major bleeding and MACE: 1295 vs. 1908 respectively. Most importantly, our meta-analysis shows that there is a treatment interaction in three subgroups: non-smokers, male sex, and treatment with statins.

Two recently published meta-analyses have provided information about the use of aspirin in primary prevention of CVD \[[@CR39], [@CR40]\]. Our meta-analysis confirms previous findings and provides additional value with four distinct subgroup analyses and a mortality-adjusted net clinical benefit analysis.

One of the most important findings of our study is the net clinical benefit of aspirin, adjusted for the risk of event-associated mortality, which aims to balance the preventive impact of aspirin on risk for ischemic events such as MI and IS, versus the impact of increased risk of bleeding. The outcome of intracranial hemorrhage is generally worse than the outcome of IS or MI, with the best outcome following a GI bleeding event. Based on previous estimates \[[@CR31], [@CR32]\], we weighted hemorrhagic stroke threefold worse than IS. Our weighted analysis provides quantitative assessments of the net clinical benefit of aspirin among primary CVD prevention patients and confirms the result of the crude net clinical benefit estimation. Although models adjusting for event-associated mortality are commonly used \[[@CR31], [@CR32]\], weighting one nonfatal event against another is very difficult, as the risks might differ between patients. Therefore, it is still unclear how to properly weight an ischemic event against a bleeding event. Some people with a high risk of having an ischemic event will prefer to take the risk of having a GI-bleed on aspirin, in order to reduce the risk of IS or MI. As there was no significant difference in mortality, intracerebral hemorrhage, or hemorrhagic stroke between aspirin and control, patient preferences should be considered.

Considering upper GI bleeding, which is the most common complication in patients under antiplatelet therapy \[[@CR41]--[@CR43]\], PPIs have been proven effective in the prevention of GI bleeding and are recommended in patients at increased risk for this bleeding \[[@CR44]\]. On the other hand, long-term treatment with PPIs is associated with increased risk of community-acquired pneumonia (CAP) \[[@CR45]\], bone fractures \[[@CR45], [@CR46]\], and enteric infections, mainly by *Salmonella* and *Campylobacter* spp. \[[@CR45]\]. Furthermore, PPI-related hypomagnesemia is of clinical significance as it is a known cause of cardiac arrhythmias \[[@CR45]\]. Thus, in consideration of the benefits and risks of the respective treatments, the question arises as to whether patients without bleeding risk should receive long-term treatment with PPIs concomitantly with aspirin for primary prevention.

A population of special interest is patients treated with statins. Interestingly, our subgroup analysis comprising 18,000 patients who were concomitantly treated with statins and aspirin showed a benefit in terms of MACE reduction, whereas those treated with aspirin without statins did not. Remarkably, patients treated with aspirin and statins showed the highest RRR of MACE of 12% compared to the overall population and patients with DM. A possible explanation for this interaction might be the consideration that those taking statins are at higher risk for CVD because of hyperlipidemia, and therefore might benefit more. Another possible elaboration might be a direct plaque-stabilizing effect of statins, which, in combination with platelet inhibition by aspirin, improves ischemic outcome. Notably, statins are associated with reduced platelet reactivity and improved response to aspirin \[[@CR47]--[@CR52]\]. However, it is unclear whether the improved response to aspirin under statin treatment is caused directly by statin-platelet interaction, indirectly via reduced levels of lipids \[[@CR47]--[@CR49], [@CR51], [@CR52]\], or by a combination of the two. Elevated cholesterol levels have been linked to decreased aspirin-induced platelet acetylation, explaining the indirect effect of statins on platelet inhibition \[[@CR53]\]. Two mechanisms have been identified as being involved in the direct effect of statins on platelets \[[@CR54]\]. Administration of atorvastatin resulted in the downregulation of phospholipase A2 (PLA2) (after 24 h) and NOX2 (after 2 h) leading to reduced levels of TxA~2~ and prothrombotic platelet isoprostanes respectively \[[@CR55]\]. Based on these findings, early and late antiplatelet effects of statins have been hypothesized \[[@CR54]\].

Interestingly, our subgroup analysis showed aspirin use in non-smokers to reduce the risk of MACE by 10%, whereas smokers did not benefit from aspirin treatment. This confirms the result of a previous meta-analysis by Seidu et al., who describe a 30% risk reduction with aspirin in non-smokers \[[@CR56]\]. Smoking has been linked to an attenuated antiplatelet effect of aspirin in the past \[[@CR57]--[@CR59]\], and our meta-analysis suggests a possible translation of this phenomenon into clinical practice. In current smokers, a treatment switch from aspirin to the P2Y~12~ receptor inhibitor clopidogrel seems to be an interesting alternative. Smoking is a known inducer of cytochrome P450 (CYP) 1A2, an essential isoenzyme that converts clopidogrel into its active metabolite, and thus may facilitate an adequate platelet inhibition \[[@CR60]\]. Studies have demonstrated fewer ischemic events in smokers following clopidogrel administration \[[@CR61], [@CR62]\]; however, in primary prevention of CVD, the overall role of clopidogrel has not yet been investigated.

It is crucial to note that our meta-analysis has shown sex differences in aspirin effects. Aspirin showed a reduction of MACE in men but not in women. In contrast, aspirin reduced the risk of stroke in women as shown in a single study, but not in men. Results from previous meta-analyses have also detected a more pronounced effect of aspirin for MACE or MI in men and for stroke in women \[[@CR5], [@CR63]--[@CR65]\]. Although sex differences in aspirin effects are of interest, it is currently unclear how they can be used in clinical decision-making \[[@CR8], [@CR16], [@CR66]\].

Another population of special interest is patients with DM. Diabetes increases the risk of CVD, and aspirin is therefore expected to have a greater preventive effect in these patients \[[@CR67]\]. In our subgroup analysis comprising over 20,000 patients with diabetes mellitus, aspirin showed a significant 9% RRR in MACE, which confirms the estimate in the overall population. While older guidelines have deemed the use of aspirin reasonable in certain patient populations with diabetes \[[@CR66]\], current 2019 guidelines from the ACC/AHA do not specifically comment on the use of aspirin in diabetic patients in primary prevention of CVD \[[@CR15]\]. The newly published ESC guidelines on diabetes, pre-diabetes, and CVD have stated aspirin may be used in patients with DM at high/very high risk of CVD and in the absence of clear contraindications (class IIb) \[[@CR68]\].

In the general population, the U.S. Preventive Services Task Force's guideline recommends aspirin for patients based on age and prediction tools such as the 10-year cardiovascular disease calculator \[[@CR16]\]. Importantly, these recommendations are given with a moderate evidence level (B and C). The 2019 ACC/AHA guidelines acknowledge the controversy of aspirin in primary prevention of CVD, but state that aspirin might be considered in selected adults aged 40 to 70 who are at higher CV risk but at no increased bleeding risk \[[@CR15]\]. Additionally, two cost-utility analyses suggest a clear benefit of aspirin \[[@CR69], [@CR70]\]. However, the ESC guidelines on CVD prevention do not recommend the general use of aspirin for the primary prevention of cardiovascular disease \[[@CR8]\].

Limitations {#Sec17}
-----------

The main limitation is that some studies did not differentiate between ischemic and hemorrhagic stroke. In such cases, the total of "all strokes" was included. The primary endpoint and follow-up periods also differed between some studies; we have adjusted for this in the sensitivity analyses. Another limitation of this meta-analysis was the use of heterogeneous definitions of major bleeding. One study used the GUSTO bleeding classification \[[@CR17]\]; most others used a prespecified composite of bleeding events such as GI bleeding and major extracranial bleeding and defined their severity by hospitalization, prolongation of hospitalization, surgery, transfusion requirement, or fatality. The severity and definition of GI bleeding events were often not further detailed.

Furthermore, some trials included in our meta-analysis \[[@CR25], [@CR27], [@CR28], [@CR30]\] were performed several decades ago. Since then, there may have been changes in medical standards, the prevalence of risk factors, and access to early diagnostic services.

Conclusions {#Sec18}
===========

The increased risk of major bleeding and lack of reduction of mortality might outweigh the benefits of aspirin in primary prevention of CVD in the overall population. Three patient subgroups: non-smokers, patients treated with statins, and males, had the greatest risk reduction of MACE.
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**Additional file 1:** **Figure S1.** Workflow of studies included in the meta-analysis. **Figure S2.** Forest plots depicting the relative risk (RR) of the (A) Primary efficacy outcome (all-cause mortality), (B) MACE and (C) primary safety outcome (major bleeding). **Figure S3.** Forest plots depicting the relative risk (RR) of the (A) Primary efficacy outcome (all-cause mortality), (B) MACE and (C) primary safety outcome (major bleeding). **Figure S4.** Forest plots depicting the relative risk (RR) of (A) extracranial major bleeding, (B) hemorrhagic stroke, (C) gastrointestinal (GI) bleeding and (D) intracranial hemorrhage. **Figure S5.** Forest plot depicting the relative risk (RR) of cancer. **Figure S6.** Forest plot depicting the crude net clinical benefit (NCB) analysis. **Table S1.** Random-effect and fixed-effect models calculated for primary, secondary and exploratory outcomes.
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